The ELUVIA Drug-Eluting Vascular Stent System is intended to improve luminal diameter in the treatment of symptomatic de-novo or restenotic lesions in the native superficial femoral artery (SFA) and/or proximal popliteal artery with reference vessel diameters (RVD) ranging from 4.0-6.0 mm and total lesion lengths up to 190 mm.

CONTRAINDICATIONS

• Women who are pregnant, breastfeeding, or plan to become pregnant in the next 5 years should not receive an ELUVIA Drug-Eluting Stent. It is unknown whether paclitaxel will be excreted in human milk, and there is a potential for adverse reaction in nursing infants from paclitaxel exposure.
• Patients who cannot receive recommended anti-platelet and/or anti-coagulant therapy.
• Patients judged to have a lesion that prevents proper placement of the stent or stent delivery system.
•  

WARNINGS

A signal for increased risk of late mortality has been identified following the use of paclitaxel-coated balloons and paclitaxel-eluting stents for femoropopliteal arterial disease beginning approximately 2-3 years post-treatment compared with the use of non-drug coated devices. There is uncertainty regarding the magnitude and mechanism for the increased late mortality risk, including the impact of repeat paclitaxel-coated device exposure. Physicians should discuss this late mortality signal and the benefits and risks of available treatment options with their patients. See Section 8.1 of the DFU for further information.

• The delivery system is not designed for use with power injection systems.
• Only advance the stent delivery system over a guidewire.
• The stent delivery system is not intended for arterial blood monitoring.
• In the event of complications such as infection, pseudoaneurysm or fistula formation, surgical removal of the stent may be required.
• Do not remove the thumbwheel lock prior to deployment. Premature removal of the thumbwheel lock may result in an unintended deployment of the stent.
• It is strongly advised that the treating physician follow the Inter-Society Consensus (TASC II) Guidelines recommendations (or other applicable country guidelines) for antiplatelet therapy pre-procedure to reduce the risk of thrombosis. Post-procedure dual antiplatelet therapy is required for a minimum of 60 days. 

PRECAUTIONS

• Stenting across a bifurcation or side branch could compromise future diagnostic or therapeutic procedures.
• The stent is not designed for repositioning.
• Once the stent is partially deployed, it cannot be "recaptured" or "reconstrained" using the stent delivery system.
• The stent may cause embolization from the site of the implant down the arterial lumen.
• This product should not be used in patients with uncorrected bleeding disorders or patients who cannot receive anticoagulation or antiplatelet aggregation therapy.
• Persons with a known hypersensitivity to paclitaxel (or structurally-related compounds), to the polymer or its individual components (see details in Primer Polymer and Drug Matrix Copolymer Carrier section), nickel, or titanium may suffer an allergic response to this implant.
• Persons with poor kidney function may not be good candidates for stenting
• procedures.

PROBABLE ADVERSE EVENTS

Probable adverse events which may be associated with the use of a peripheral stent include but are not limited to:

• Allergic reaction (to drug/polymer, contrast, device or other):
• Amputation
• Arterial aneurysm
• Arteriovenous fistula
• Death
• Embolization (air, plaque, thrombus, device, tissue, or other)
• Hematoma
• Hemorrhage (bleeding)
• Infection/Sepsis
• Ischemia
• Need for urgent intervention or surgery
• Pseudoaneurysm formation
• Renal insufficiency or failure
• Restenosis of stented artery
• Thrombosis/thrombus
• Transient hemodynamic instability (hypotensive/hypertensive episodes)
• Vasospasm
• Vessel injury, including perforation, trauma, rupture and dissection
• Vessel occlusion

Probable adverse events not captured above that may be unique to the paclitaxel drug coating:

• Allergic/immunologic reaction to drug (paclitaxel or structurally-related compounds) or the polymer stent coating (or its individual components)
• Alopecia
• Anemia
• Gastrointestinal symptoms
• Hematologic dyscrasia (including leukopenia, neutropenia, thrombocytopenia)
• Hepatic enzyme changes
• Histologic changes in vessel wall, including inflammation, cellular damage or necrosis
• Myalgia/Arthralgia
• Peripheral neuropathy